Publications by authors named "Rebeca Melara"

Claim this Profile
A
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection.
Katherine E Squires, Lauren Ogilvie, Alina Jucov, Igor Anastasiy, Nelli Ghicavii, Rebeca Melara

J Viral Hepat· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies.
Benjamin Wu, Rebeca Melara, Erik Rasmussen, Lei Zhou, Teresa Wong

Cancer Chemother Pharmacol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Ignace Vergote, Russell J Schilder, Charles H Pippitt, Shirley Wong, Alan N Gordon, Rebeca Melara

Gynecol Oncol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
Richard H De Boer, Dusan Kotasek, Shane White, Bogda Koczwara, Paul Mainwaring, Rebeca Melara

Breast Cancer Res Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Jian-Feng Lu, Erik Rasmussen, Beth Y Karlan, Ignace B Vergote, Lynn Navale, Rebeca Melara

Cancer Chemother Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism.
Yow-Ming C Wang, Bethlyn Sloey, Teresa Wong, Prerna Khandelwal, Rebeca Melara

Pharm Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Jian-Feng Lu, Laurent Claret, Liviawati Sutjandra, Mita Kuchimanchi, Rebeca Melara

Cancer Chemother Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Patricia Lorusso, Elisabeth I Heath, Jesse McGreivy, Yu-Nien Sun, Rebeca Melara

Invest New Drugs· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis